Radiopharmaceutical publicly funded in some provinces has fewer side effects than chemotherapy and can increase survival by ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug Administration (FDA) for expanded prostate cancer use.

Pluvicto’s (lutetium Lu 177 vipivotide tetraxetan) dosage for metastatic prostate cancer is 7.4 GBq given every 6 weeks. It’s important to follow the Pluvicto dosage your doctor prescribes.

The article continued: The number of annual cancer cases is expected to rise by 20% by 2030 and jump by 75% by 2050, ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Last year, nearly half a million cancer patients received life-saving treatments, from a medicine, that's active ingredient was created at Mizzou.

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by ...

The FDA has expanded Pluvicto's indication for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. Selection for Pluvicto should be based on PSMA expression using ...